Quest Diagnostics Incorporated (DGX)
| Market Cap | 26.40B +29.1% |
| Revenue (ttm) | 11.56B +9.9% |
| Net Income | 1.06B +11.8% |
| EPS | 9.42 +12.8% |
| Shares Out | 110.37M |
| PE Ratio | 25.40 |
| Forward PE | 20.88 |
| Dividend | $3.44 (1.44%) |
| Ex-Dividend Date | Oct 6, 2026 |
| Volume | 1,002,728 |
| Open | 235.85 |
| Previous Close | 233.43 |
| Day's Range | 235.57 - 239.17 |
| 52-Week Range | 171.18 - 248.84 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 251.40 (+5.12%) |
| Earnings Date | Oct 22, 2026 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $251.4, which is an increase of 5.12% from the latest price.
News
Quest Diagnostics price target raised to $260 from $250 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $250 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Quest Diagnostics’ Haystack MRD shows efficacy in colorectal cancer detection
Quest Diagnostics (DGX) announced that a new study published in The Journal of Molecular Diagnostics showed that Quest’s Haystack MRD test is highly accurate at detecting residual and recurrent diseas...
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS...
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 finan...
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more th...
Quest Diagnostics price target raised to $260 from $250 at Truist
Truist raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $250 and keeps a Hold rating on the shares as part of a broader research note updating…
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are schedule...
Quest Diagnostics Transcript: 2026 Global Healthcare Conference
Revenue and earnings growth have outpaced long-term plans, driven by organic expansion, partnerships, and a rapidly growing consumer health segment. Strategic focus has shifted from M&A to integration and partnerships, with new executive talent and board expertise supporting this evolution. Regulatory uncertainty around PAMA remains, but advocacy for legislative solutions continues.
Quest Diagnostics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
2026 guidance was raised on strong first-half results, with consumer and partnership growth driving performance. Margin expansion is expected as integration costs subside and advanced diagnostics, consumer, and digital partnerships accelerate. Market share gains and robust M&A activity support a positive long-term outlook.
Apple Health app users can order labs from Quest Diagnostics
Quest Diagnostics (DGX) announced that Apple (AAPL) Health app users in the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50…
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026...
Quest Diagnostics price target raised to $245 from $232 at UBS
UBS raised the firm’s price target on Quest Diagnostics (DGX) to $245 from $232 and keeps a Neutral rating on the shares.
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /...
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financ...
Quest Diagnostics to offer FDA-cleared Roche pTau217 blood test
Quest Diagnostics (DGX) announced two new developments for its Quest AD-Detect portfolio of blood-based biomarker tests for Alzheimer’s disease, with the goal of broadening access to quality blood tes...
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with lo...
WHOOP Makes Advanced Labs Available Without a Wearable Membership
BOSTON--(BUSINESS WIRE)--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first t...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend...
Quest Diagnostics typically performs between 30 and 40 cyclospora tests a day. Now it's processing more than 1,500.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.
Quest Diagnostics CEO: AI is helping patients understand their doctors
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxb...
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea SECAUCUS, N.J., July 30, 2026 /PRNewsw...
Quest Diagnostics price target raised to $260 from $225 at Argus
Argus raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $225 and keeps a Buy rating on the shares. The firm cites the company’s strong Q2 results…
Quest Diagnostics price target raised to $250 from $220 at JPMorgan
JPMorgan raised the firm’s price target on Quest Diagnostics (DGX) to $250 from $220 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Quest Diagnostics price target raised to $265 from $245 at BofA
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $265 from $245 and keeps a Buy rating on the shares after the company reported “solid” Q2 results and…